Study | Reason for exclusion |
---|---|
Albers 2016 | Post‐hoc analysis of observational study |
Albers 2020 | Data pooled from 2 studies, also post hoc analysis looking at participants grouped by prior omalizumab use, which is not a subgroup prespecified in our protocol |
Alvarez‐Cuesta 1994 | Intervention used in study (cat extract immunotherapy) is not anti‐IL‐5 therapy |
Armentia 1992 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Austin 2016 | Aggregation of 2 clinical trials |
Austin 2016a | Not an RCT (analysis of the characteristics of patients that entered 2 trials of mepolizumab) |
Ayres 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bardford 2018 | Post hoc analysis of mepolizumab study (MUSCA, Chupp 2017), looking at participants grouped by prior omalizumab use, which is not a subgroup prespecified in our protocol. |
Bel 2014 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
Berger 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bernstein 2020a | Not asthma (wrong disease group) |
Bjermer 2017 | Only pooled data (from > 1 RCT) presented |
Blanken 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Blanken 2013 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
Bleecker 2018a | Data pooled from 2 studies |
Bleecker 2018b | Only pooled data (from > 1 RCT) presented |
Boulet 1997 | Intervention used in study (anti‐IgE antibody e25) is not anti‐IL‐5 therapy |
Bourdin 2018 | Post hoc analysis of reslizumab study looking at patients grouped by presence or absence of allergen‐specific IgE, which is not a subgroup prespecified in our protocol. |
Bourdin 2020 | This is not an RCT (it is a type of meta‐analysis of other RCTs) |
Bousquet 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bousquet 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Brightling 2014 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Brown 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Brusselle 2016 | Aggregation of 2 clinical trials |
Brusselle 2017 | Data pooled from 2 studies, also post hoc analysis looking at participants grouped by baseline step 4/5 therapy, which is not a subgroup prespecified in our protocol. |
Bryant 1975a | Not a RCT |
Bryant 1975b | Not a RCT |
Buhl 2000a | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
Buhl 2000b | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
Buhl 2002 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Bush 1985 | Intervention used in study (soybean oil) is not anti‐IL‐5 therapy |
Busse 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Busse 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Busse 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Buttner 2003 | Treatment < 16 weeks |
Caffarelli 2000 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Canvin 2016 | Aggregation of 2 clinical trials |
Carr 2017 | Data pooled from 2 studies |
Carr 2019 | Only pooled data (from > 1 RCT) presented |
Castro 2011 | < 16 weeks in length |
Castro 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Castro 2018 | Data pooled from 2 studies, also post hoc analysis looking at participants grouped by whether screening and baseline eosinophils > 400 or not, which is not a subgroup prespecified in our protocol |
Chandra 1989 | Intervention used in study (various foods) is not anti‐IL‐5 therapy |
Chanez 2017 | Only pooled data (from > 1 RCT) presented |
Chanez 2017a | Only pooled data (from > 1 RCT) presented |
Chanez 2018 | Open‐label extension not an RCT |
Chanez 2019 | Post hoc analysis of reslizumab study comparing participants who didn’t have a blood eosinophil response to reslizumab to those who did, which is not a subgroup prespecified in our analysis |
Chauhan 2017 | Only pooled data (from > 1 RCT) presented |
Chervinsky 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Chipps 2017 | Pooled data only (from SIROCCO (Bleecker 2016) and CALIMA FitzGerald 2016) studies; data are already in the analysis) |
Chipps 2018 | Only pooled data (from > 1 RCT) presented |
Chipps 2019 | Only pooled data (from > 1 RCT) presented |
Chipps 2020 | Only pooled data (from > 1 RCT) presented |
Clavel 1998 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Corren 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Corren 2010 | Intervention used in study (il‐4r alpha antagonist) is not anti‐IL‐5 therapy |
Cullell‐Young 2002 | Not a RCT |
Dasgupta 2016 | Participants did not have a diagnosis of asthma (COPD patients) |
De Boever 2014 | Intervention used in study (anti‐IL‐13 mab) is not anti‐IL‐5 therapy |
Djukanovic 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
DuBuske 2018 | Data pooled from 2 studies |
Ebner 1989 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Eckman 2010 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
El‐Nawawy 2000 | Not a RCT |
EUCTR2012‐004385‐17‐BE | The study participants did not have asthma |
EUCTR2015‐001152‐29‐BE | Not an RCT and endpoints are not applicable as this is a long‐term access programme |
EUCTR2016‐001831‐10‐NL | No placebo arm/single treatment arm and treatment duration < 16 weeks |
EUCTR2016‐002405‐19‐DE | Participants do not have a diagnosis of asthma, no placebo arm, treatment duration < 16 weeks |
EUCTR2017‐003958‐16‐NL | Treatment duration < 16 weeks (12 weeks) |
Fahy 1997 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Fahy 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Ferguson 2016a | Benralizumab for mild to moderate, persistent asthma: the BISE phase III study ‐ duration < 16 weeks (12 weeks) |
Ferguson 2016b | Treatment duration < 16 weeks in length |
Ferguson 2017 | Study duration < 16 weeks (12 weeks) |
Finn 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
FitzGerald 2017a | Post hoc analysis of CALIMA (FitzGerald 2016), benralizumab study looking at the subset of patients from Japan, which is not a subgroup prespecified in our protocol. |
FitzGerald 2017b | Only pooled data (from > 1 RCT) presented |
FitzGerald 2018 | Only pooled data (from > 1 RCT) presented |
Fitzgerald 2019 | 2‐year safety study including 1 year in RCT (3 studies pooled) and 1 year open‐label extension |
Flood‐Page 2003 | Treatment < 16 weeks |
Flood‐Page 2007 | Treatment < 16 weeks |
Frew 1998 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Garcia 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Garin 2019 | Only pooled data (from > 1 RCT) presented |
Gauvreau 2011 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
Gauvreau 2014a | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
Gauvreau 2014b | Intervention used in study (anti‐tslp) is not anti‐IL‐5 therapy |
Gauvreau 2014c | Intervention used in study (OX40L antagonist) is not anti‐IL‐5 therapy |
Gauvreau 2015a | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
Gauvreau 2015b | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
Gevaert 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Gibson 2021 | Wrong study design |
Goldman 2017 | Only pooled data (from > 1 RCT) presented |
Gopalan 2017a | Data pooled from 2 studies |
Gopalan 2017b | Data pooled from 2 studies |
Gordon 1972 | Intervention used in study is not anti‐IL‐5 therapy |
Greenberg 1991 | Participants do not have a diagnosis of asthma |
Gunsoy 2016 | Not a randomised, placebo‐controlled trial |
Han 2009 | Intervention used in study (jade screen powder) is not anti‐IL‐5 therapy |
Hanania 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hanania 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hanania 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Hanania 2015 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Harris 2016 | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
Hendeles 2015 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hickey 2019 | Only pooled data (from > 1 RCT) presented |
Hill 1982 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Hodsman 2013 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
Holgate 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Hoshino 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Howarth 2020 | Study focused on nasal polyps rather than asthma |
Humbert 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Humbert 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Humbert 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Humbert 2017 | Post hoc analysis looking at participants in a reslizumab trial (BREATH) grouped by omalizumab eligibility, which is not a subgroup prespecified in our protocol |
Humbert 2019 | Data pooled from 2 mepolizumab studies (MENSA, MUSCA), post hoc analysis looking at participants grouped by omalizumab eligibility, which is not a subgroup prespecified in our protocol |
Iino 2019 | Study in eosinophilic otitis media not asthma |
Jackson 2019 | Pooled data only from trials that are already included (Bleecker 2016; FitzGerald 2016) |
Jacobs 2018 | Pooled data only from trials that are already included (Castro 2015a; Castro 2015b) |
Jacquemin 1995 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Jimenez 2019 | Aggregation of 5 studies |
Jutel 2005 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Kang 1988 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Katial 2019 | Subgroup analysis by subgroups not relevant to our protocol |
Katial 2020 | Post hoc analysis of benralizumab study looking at patients grouped by high or low FeNO, which is not a subgroup prespecified in our protocol |
Kim 2020 | Pooled data only: mepolizumab IV (Pavord 2012a), and mepolizumab SC (Ortega 2014) |
Kips 2003 | Treatment < 16 weeks |
Kon 2001 | Intervention used in study (anti‐cd4) is not anti‐IL‐5 therapy |
Kopp 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Kopp 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Korenblat 2018 | Only pooled data (from > 1 RCT) presented |
Kreindler 2019 | Pooled data only from trials that are already included (Bleecker 2016; FitzGerald 2016) |
Kuang 2018 | Not asthma (hypereosinophilic syndrome) |
Kuang 2019 | Not asthma (hypereosinophilic syndrome) |
Kulus 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Lam 2018 | Not a RCT (cost‐effectiveness analysis incorporating multiple inputs, including but not only data from 2 RCTs) |
Lanier 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Lanier 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Laviolette 2013 | Treatment < 16 weeks |
Leckie 2000 | Treatment < 16 weeks |
Leynadier 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Li 2016 | Review article, not a RCT |
Lizaso 2008 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Lugogo 2016 | Not a randomised, placebo‐controlled trial |
Lugogo 2020 | The intervention includes a reduction in standard asthma management (OCS maintenance), and as per our protocol, we have excluded such studies as the heterogeneity in study design makes them too dissimilar to compare |
Manning 2018 | Only pooled data (from > 1 RCT) presented |
Maselli 2017 | Trial involves OCS dose reduction (1 of our exclusion criteria) |
Maspero 2016 | Combined secondary analysis of 2 trials |
Maspero 2018 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Maspero 2019 | Only pooled data (from > 1 RCT) presented |
Massanari 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Massanari 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Mathur 2019 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Mathur 2020 | Only pooled data (from > 1 RCT) presented |
Maunoury 2018 | Not a RCT |
Menzies‐Gow 2019a | Trial involves OCS dose reduction (one of our exclusion criteria) |
Menzies‐Gow 2019b | Trial involves OCS dose reduction (one of our exclusion criteria) |
Metzger 1998 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Milgrom 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
Milgrom 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Modlin 1977 | Participants do not have diagnosis of asthma |
Moran 2020 | Not an RCT (observational study of patients with asthma and COPD) |
Moss 1987 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Murphy 2018 | Only pooled data (from > 1 RCT) presented |
Nair 2009 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
Nair 2016 | All participants do not have a diagnosis of asthma |
Nair 2017a | Trial involves OCS dose reduction (1 of our exclusion criteria) |
Nair 2017b | Substudy of a trial involving OCS dose reduction (one of our exclusion criteria) |
Nair 2017c | Trial involves OCS dose reduction (one of our exclusion criteria) |
Nair 2020 | Only pooled data (from > 1 RCT) presented |
NCT00783289 | Treatment duration < 16 weeks |
NCT00802438 | Not RCT |
NCT01290887 | Study does not include a placebo arm |
NCT01366521 | Phase 2 study comparing three doses of mepolizumab. This trial does not have a placebo arm. |
NCT01471327 | Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose SB‐240563 administered IV to Japanese healthy male participants. People with asthma were not included in the study. |
NCT01520051 | Duration < 16 weeks, additional intervention (experimental rhinovirus infection) |
NCT01691859 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered SC (no control group) |
NCT01842607 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered SC (no control group) |
NCT02020889 | The study participants did not have asthma |
NCT02075255 | Focus of trial is on oral steroid reduction |
NCT02135692 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term study of SC administered mepolizumab 100 mg in addition to standard care, in participants with severe eosinophilic asthma |
NCT02258542 | Not a RCT (an extension study with no placebo arm) |
NCT02293265 | Aim of study is to provide a "reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab". No pharmaceutical intervention in study |
NCT02377427 | Treatment period < 16 weeks |
NCT02417961 | Not a RCT |
NCT02501629 | Focus of trial is on oral steroid reduction |
NCT02559791 | Not placebo‐controlled ‐ single treatment arm only |
NCT02594332 | Study terminated (recruitment problems) |
NCT02654145 | Not placebo‐controlled. Single treatment arm only |
NCT02808819 | Not an RCT |
NCT02814643 | Treatment duration < 16 weeks |
NCT02821416 | Duration < 16 weeks, additional intervention (allergen challenge) |
NCT02869438 | Treatment duration < 16 weeks |
NCT02937168 | Treatment duration < 16 weeks |
NCT02968914 | Not a placebo‐controlled trial |
NCT03014674 | Not a placebo‐controlled trial and treatment duration < 16 weeks |
NCT03021304 | No placebo arm/single treatment arm, treatment duration < 16 weeks |
NCT03476109 | No placebo comparator |
NCT04617171 | Treatment of participants with acute asthma exacerbation, not chronic asthma |
NCT04710134 | Ineligble study design |
Nelsen 2019 | Pooled data from 2 trials (Chupp 2017; Ortega 2014), and a 3rd observational study |
Newbold 2016 | Not an RCT |
Newbold 2017 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Niven 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Noga 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Noga 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Noonan 2013 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Nowak 2015 | Treatment < 16 weeks |
O'Quinn 2019 | Only pooled data (from > 1 RCT) presented |
Oba 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Oh 2013 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
Ohashi 1997 | Participants do not have a diagnosis of asthma |
Ohman 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Ohta 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Ohta 2017 | Post hoc analysis of CALIMA (FitzGerald 2016), benralizumab study looking at the subset of patients from Japan, which is not a subgroup prespecified in our protocol |
Ong 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Ortega 2018a | Only pooled data (from > 1 RCT) presented |
Ortega 2018b | Only pooled data (from > 1 RCT) presented |
Panettieri 2017 | Post hoc analysis of reslizumab study looking at participants who had an FEV1 < 50%, which is not a subgroup prespecified in our analysis |
Park 1998 | Not an RCT |
Park 2018 | Post hoc analysis of SIROCCO (Bleecker 2016), benralizumab study looking at the subset of patients from Korea, which is not a subgroup prespecified in our protocol |
Park 2019 | Post hoc analysis of SIROCCO (Bleecker 2016) benralizumab study looking at the subset of patients from Korea, which is not a subgroup prespecified in our protocol |
Parker 2010 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
Pauli 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
Pavord 2012 | Posthoc analysis of Pavord 2012a and Ortega 2014 stratified by prior use of anti‐IgE therapy |
Pelaia 2016 | Study is not an RCT |
Pham 2016 | An analysis of sera collected from asthma patients enrolled in 2 clinical studies |
Piper 2012 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Piper 2013 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Pouliquen 2015 | Study has no placebo arm or clinical endpoints |
Pouliquen 2016 | Aggregation of 2 clinical trials |
Prazma 2016 | Study is not a randomised, placebo controlled trial |
Prieto 2006 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Pui 2010 | Intervention used in study (air/diesel exhaust +/‐ antioxidant) is not anti‐IL‐5 therapy |
Ranade 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
Rose 2009 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
Roskos 2018 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Roufosse 2020 | Not asthma (hypereosinophilic syndrome) |
Sakamoto 1984 | Not an RCT |
Scheerens 2011 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Scheerens 2012 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Scheerens 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
Shaw 2019 | Trial involves oral corticosteroid dose reduction (one of our exclusion criteria). |
Shrimanker 2018 | Only pooled data (from > 1 RCT) presented |
Shrimanker 2019 | Only pooled data (from > 1 RCT) presented |
Siergiejko 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Silk 1998 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
Silkoff 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Simoes 2007 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
Singh 2010 | Intervention used in study (anti‐IL‐13) is not anti‐IL‐5 therapy |
Slavin 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Soler 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Sorkness 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Steinfeld 2020 | Not asthma (hypereosinophilic syndrome) |
Sthoeger 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Sugaya 1994 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
Swanson 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Szymaniak 1998 | Not an RCT |
Tanaka 1993 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
Terr 1969 | Study predates monoclonal treatments |
Vanlandingham 2019 | Only pooled data (from > 1 RCT) presented |
Van Rensen 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Vignola 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Virchow 2016 | Aggregation of 2 clinical trials |
Virchow 2017 | Only pooled data (from > 1 RCT) presented |
Virchow 2019 | Only pooled data (from > 1 RCT) presented |
Virchow 2020 | Only pooled data (from > 1 RCT) presented |
Virchow 2020a | Only pooled data (from >1 RCT) presented |
Wang 2015 | Pharmacometrics assessment of phase IIb data to characterise the exposure‐response relationship with benralizumab in adults with asthma |
Wang 2017 | Only pooled data (from > 1 RCT) presented |
Wark 2003 | Intervention used in study (itraconazole) is not anti‐IL‐5 therapy |
Wechsler 2017 | Pooled data from 2 trials (Castro 2015a; Castro 2015b) |
Wechsler 2017a | Only pooled data (from > 1 RCT) presented |
Wechsler 2019 | Only pooled data (from > 1 RCT) presented |
Wechsler 2020 | Post hoc analysis of reslizumab studies looking at participants who had ≥ 2 or ≥ 3 exacerbations, which is not a subgroup prespecified in our analysis |
Weinstein 2016 | Combined secondary analysis of 2 trials |
Wenzel 2009 | Intervention used in study (golimumab) is not anti‐IL‐5 therapy |
Wenzel 2013 | Interventionused in study (dupilumab) is not anti‐IL‐5 therapy |
Wenzel 2013a | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Wenzel 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
Xu 2017 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Xu 2018 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Yan 2015 | Participants do not have a diagnosis of asthma |
Yancey 2017 | Analysis of subgroup not relevant to our protocol (participants with ≥ 3 exacerbations and eosinophils ≥ 300/μL) |
Yancey 2020 | Analysis of subgroup not relevant to our protocol |
Zangrilli 2019 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
Zetterstrom 1972 | Participants do not all have diagnosis of asthma |
Zhu 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
Zielen 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
COPD: chronic obstructive pulmonary disease; FeNO: exhaled fraction of nitric oxide; IV: intravenous; OCS: oral corticosteroid; RCT: randomised controlled trial; SC: subcutaneous